tiakis Biotech AG and Northway Biotech collaborate

Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat

tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension.

tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life threatening surgeries and life-threatening diseases such as PAH and COVID-19.
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life threatening surgeries and life-threatening diseases such as PAH and COVID-19. (Image: ©stock.adobe.com/Gorodenkoff)

For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.

“The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis’ development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example,” said Martin Voss, tiakis Biotech AG co-CEO. 

The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania

Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis’ deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations.”

André Markmann, VP Business Development of Northway Biotech, added: “This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."

By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.

More News

Tiprelestat will be administered to patients hospitalized due to COVID-19 with the goal of reducing the duration of severe COVID-19.
Tiprelestat will be administered to patients hospitalized due to COVID-19 with the goal of reducing the duration of severe COVID-19. (Photo Credit: Alissa Eckert, MSMI; Dan Higgins, MAMS)

tiakis: Treatment of COVID-19

tiakis Biotech AG announced today that a first patient has been dosed in the COMCOVID trial, a Phase Ib/II trial evaluating the Company’s key investigational ...

Read more …